egnite Research

Advancing cardiovascular research through egnite’s real-world evidence.

egnite Launches CardioCare Research Suite to Accelerate Patient Identification for Leading Cardiovascular Clinical Trials

ALISO VIEJO, Calif. – July 1, 2025 – egnite, Inc., a leading digital health company advancing cardiovascular innovation, today announced the launch of its new CardioCare Research Suite, a significant expansion of its flagship platform that enables hospitals to automatically identify patients eligible for clinical trials across participating health systems.

Read More »

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient

Read More »
Figure 1: Observed Mortality Stratified by GLP-1 RA and/or SGLT2i Prescription

Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis

BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized,

Read More »